FDA Guidelines focusing on the preventative care for common health problems as patients with HIV live longer.

Flashes associated with menopause and to prevent osteoporosis after menopause.

Pimavanserin is shown to be beneficial in alleviating symptoms of psychosis in patients with Parkinson’s disease.

A series of preliminary studies shows that an inhaled dual phosphodiesterase inhibitor, inhibiting phosphodiesterases 3 and 4, is promising against asthma and chronic obstructive pulmonary disease.

Over misleading marketing messages for its schizophrenia drug Risperdal.

Imbruvica (ibrutinib) approved for use to treat patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

The recalled products contained aegeline, a new dietary ingredient that lacks a history of use or evidence of safety.

We can help with specific cases. This newsletter is supported by the University of Louisiana at Monroe College of Pharmacy and is not intended for

The European Association of Urology has released guidelines on the diagnosis and treatment of patients with primary

Access to full

CDC: Provisional Guidelines for Multidrug

The new guidelines include the Prevention and Treatment of Opportunistic Infections Among HIV

Adempas FDA Approved

FDA Approves Opsumit

New Treatment Option for Parkinson’s Psychosis

FDA Approves Imbruvica

Three hydrocodone combination drugs such as Vicodin by early December.

HIV Vaccine Candidate Fails to Protect

A small study showed that stem

Stem

Qsymia for Weight Loss

OTCs Now Eligible FSA Expenses

Janssen Pharm to Plead Guilty For Misleading Marketing

FDA Notification: Be Inspired

FDA Issues Drug Safety Concern: Iclusig (Ponatinib)

Three

FDA Advisory Committee Recommends Against Bevacizumab as First-Line Treatment for Metastatic Breast Cancer

Nephron Pharmaceuticals recalls ten lots of the product as a precaution to aseptic process monitoring.

FDA indicates safety concerns over Iclusig (Ponatinib);

Three

FDA announces preliminary determination that partially hydrogenated oils are not “generally recognized as safe” for use

The results of a clinical trial suggest that gabapentin is beneficial in treating alcohol dependence when compared to placebo.

According to the USPSTF, there is not enough evidence regarding the use of vitamin and mineral supplementation in primary

FDA approves medical device to treat epilepsy

FDA confirms safety concerns over Iclusig (Ponatinib);

Three

Ninety Patients on Statin Treatment Reporting Gastrointestinal Problems

Anaphylaxis in Patients Allergic to Penicillin

The DIC has a new phone number and provides information services exclusively to the healthcare professionals

Drug Approvals

News Items

Medication Errors

To serve as an information resource center for faculty, students, and healthcare professionals.

We hope you find this newsletter helpful in

Pharmacy!